Predictive Toxicology Summit 2014

Applying in silico, in vitro and in vivo models to mitigate clinical failure.

As demonstrated by Vioxx and Exanta, failing to identify adverse effects of new drugs can be financially devestating. With budget cuts hitting the R&D field hard, ensuring candidate compounds are safe is even more important to reduce late stage attrition and product withdrawals.

But how do we cost-effectively develop and implement these in silico, in vitro and in vivo methods as early in drug discovery and development as possible? How do we demonstrate the validation of these methods?

2014 Speakers include:

Franck Atienzar

Associate Director, In Silico and In Vitro Toxicology

UCB

Thomas Steger-Hartmann

Head of Experimental Toxicology Laboratory Diagnostics

Bayer AG

Harald Kropshofer

Senior Personalized Healthcare Leader, Pharmaceutical Development

F. Hoffman La Roche

Sridharan Rajamani

Senior Research Scientist

Gilead Sciences

and many more...